The trial, led by Chunmei Zhao and Fang Luo of Beijing Tiantan Hospital at Capital Medical University, together with colleagues at multiple centers in China and Nepal, enrolled 80 patients whose episodic cluster headache had resisted oral medications. To be eligible, participants had to present to a pain clinic within five days of the onset of a new cluster period, a narrow window that allowed the researchers to capture the natural arc of an episode from its earliest days. Patients were randomly assigned in equal numbers to one of two procedures targeting the sphenopalatine ganglion: pulsed radiofrequency treatment or a conventional nerve block. Everyone in both groups then took oral verapamil at a dose of 360 milligrams per day, the standard preventive drug for cluster headache, ensuring that the comparison isolated the effect of the procedure itself.

The sphenopalatine ganglion, also called the pterygopalatine ganglion, has long fascinated headache specialists because it acts as a major relay station for the facial pain pathways and parasympathetic autonomic signals that surge during cluster attacks. Attacks of cluster headache involve intense pain around one eye or temple, typically accompanied by tearing, nasal congestion, eyelid drooping, and restlessness, all hallmarks of trigeminal-autonomic activation in which the sphenopalatine ganglion plays a central role. Blocking this ganglion with local anesthetics has been a recognized short-term rescue strategy for years, but the effects of a nerve block fade within days. Pulsed radiofrequency, by contrast, applies brief bursts of an alternating electrical field to the ganglion through a needle electrode, generating controlled thermal and electromagnetic effects that are thought to modulate pain signaling without destroying nerve tissue, potentially offering relief that lasts for months.

The technical execution of the procedure demands precision. Under imaging guidance, clinicians advance a specialized electrode through the face to reach the pterygopalatine fossa, the small anatomical pocket where the ganglion sits, and confirm correct placement before delivering the pulsed radiofrequency cycles. In this trial the technique was performed as an add-on to verapamil rather than a replacement for it, reflecting the reality that most patients with cluster headache need layered treatment. The researchers registered the study prospectively on ClinicalTrials.gov as NCT03567590, obtained ethics approval from the Institutional Review Board of Beijing Tiantan Hospital, and followed Consolidated Standards of Reporting Trials guidelines, with a blinded-endpoint design and a Data and Safety Monitoring Board overseeing the study, features that strengthen confidence in the findings.

The primary endpoint was the duration of the cluster period, and the difference between the groups was dramatic. Patients treated with pulsed radiofrequency had a median cluster-period duration of 15.0 days, with an interquartile range of 6.2 to 30.0 days, while those treated with nerve block had a median duration of 61.0 days, with an interquartile range of 17.0 to 90.0 days. The median difference between groups was minus 34.0 days, with a 95 percent confidence interval of minus 56.0 to minus 17.0 days and a P value below 0.001, a result that is both statistically robust and clinically profound. In practical terms, patients who received the pulsed radiofrequency treatment were spared roughly an additional month of recurrent attacks compared with those receiving the standard block.

Secondary endpoints told a consistent story across nearly every measure of attack burden. Pain intensity during attacks, scored on the numerical rating scale, was significantly lower in the pulsed radiofrequency group at day 3, week 1, week 2, and month 1, with median between-group differences of minus 1.0, minus 2.0, minus 3.0, and minus 4.0 points respectively, the last representing a large shift on a scale where every point matters to a patient in agony. Attack frequency and attack duration were also significantly reduced in the pulsed radiofrequency group at week 1, week 2, month 1, and month 3, and patients used less rizatriptan, a fast-acting triptan medication taken to abort individual attacks, over the same follow-up points. By month 6 and year 1 the between-group differences on these secondary measures were no longer statistically significant, which is consistent with the episodic nature of the disease, since many patients in both groups had exited their cluster periods by then.

Safety is always a central question when a procedure involves threading an electrode near critical structures at the skull base, and the trial reported few adverse effects with pulsed radiofrequency treatment. The authors concluded that in patients with episodic cluster headache resistant to oral medications, sphenopalatine ganglion pulsed radiofrequency combined with verapamil provided greater pain relief than sphenopalatine ganglion nerve block combined with verapamil, with few adverse effects. The study was supported by the National Key Research and Development Program of China and by Capital’s Funds for Health Improvement and Research, among other funders, which had no role in the design, analysis, or decision to publish. The authors declared no competing interests, and all participants provided written informed consent before enrollment.

The implications reach beyond the immediate result. Cluster headache affects roughly one in a thousand people, and while abortive options such as subcutaneous sumatriptan, high-flow oxygen, and newer CGRP-targeting therapies exist, preventive options remain limited and verapamil, the mainstay, requires slow titration and cardiac monitoring. For patients in the midst of a cluster period, every day of shortened episode duration translates into dozens of avoided attacks, restored sleep, and reduced reliance on acute medications. If pulsed radiofrequency of the sphenopalatine ganglion can reliably compress a cluster period from two months to two weeks, it could reshape the treatment algorithm for medication-refractory episodic disease, positioning a one-time procedural intervention alongside pharmacology rather than as a last resort.

Important caveats temper the enthusiasm. The trial focused specifically on episodic cluster headache, the form in which attacks occur in bounded bouts separated by remission periods, and its results cannot be assumed to extend to chronic cluster headache, in which attacks persist for a year or more without relief. The comparison arm was an active control, a nerve block rather than a sham procedure, which is methodologically respectable but means the study cannot fully separate the specific neuromodulatory effects of pulsed radiofrequency from the general effect of any ganglion-directed intervention combined with verapamil. The sample of 80 patients, while adequate for the primary endpoint, is modest, and the open nature of the treatment delivery, with only the endpoint assessment blinded, leaves some room for expectation effects on the self-reported secondary outcomes.

Even with those limitations, the trial stands as one of the most convincing demonstrations to date that targeted neuromodulation of the sphenopalatine ganglion can alter the natural history of a cluster period rather than merely blunting individual attacks. The prospective registration, blinded endpoint assessment, multicenter recruitment, and consistent signal across primary and secondary outcomes give the finding unusual weight for a procedural pain study. For the patients who spend their cluster seasons pacing dark rooms waiting for the storm to pass, the message from this research is concrete and hopeful: a precisely delivered field of pulsed electrical energy, aimed at a ganglion the size of a grain of rice hidden behind the cheek, may cut weeks of suffering from the cruelest headache disorder medicine knows. Larger studies and replication in other populations will be needed before the procedure becomes standard practice, but the direction of the evidence now points firmly toward the sphenopalatine ganglion as the right target at the right time.

Subject of Research: Pulsed radiofrequency neuromodulation of the sphenopalatine ganglion for treating episodic cluster headache

Article Title: Efficacy and safety of sphenopalatine ganglion pulsed radiofrequency in episodic cluster headache: a randomized controlled trial

Article References: Zhao, C., Bian, J., Ren, H., Wu, D., Meng, L., Shen, Y., Wang, B., Shrestha, N., & Luo, F. (2026). Efficacy and safety of sphenopalatine ganglion pulsed radiofrequency in episodic cluster headache: a randomized controlled trial. BMC Medicine. https://doi.org/10.1186/s12916-026-05242-8

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05242-8

Keywords: cluster headache, sphenopalatine ganglion, pulsed radiofrequency, randomized controlled trial, verapamil, nerve block, neuromodulation, pain management, neurology, headache, trigeminal-autonomic, BMC Medicine